Inside informationEnglish
NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Nanobiotix
- Filed
- 24/10/2025, 08:00
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 111456_20251024